preloader

COMBOGESIC® IV

This site is intended for U.S. residents age 18 and over

Prescribing Information

Connect With Hikma

Order Product Today
Menu

PAIN MANAGEMENT

Acute Pain Management in Adults

Acute pain affects millions of patients annually and is the most common presenting complaint to emergency departments in the US1

Among nonsurgical causes, musculoskeletal injuries have accounted for over 65 million healthcare encounters, while more than 80% of surgical patients in the US experience acute postoperative pain that is not adequately managed.2,3

The Impact of Ineffective Pain Management

Despite the heightened attention and administration of analgesic medication in recent years, a significant number of patients still report inadequate postoperative pain relief.3,4

Ineffective pain management can lead to a marked decrease in desirable clinical and psychological outcomes and patients’ overall quality of life.5

Consequences Include3,4:
  • Decreased lung function
  • Infection
  • Myocardial infarction
  • Delayed recovery time
  • Prolonged opioid use
  • Sleep disturbances
  • Functional impairment
  • Increased morbidity and mortality
  • Increased hospital readmissions
  • Higher health-care costs

Evidence suggests that less than half of patients who undergo surgery report adequate postoperative pain relief6

The most effective strategy for improving pain control and decreasing adverse medication events in acute care settings is multimodal analgesia7

Multimodal Analgesia

Evidence-based recommendations emphasize the importance of a multimodal approach to pain management using multiple interventions with different mechanisms of action that may offer additive or synergistic effects to optimize pain relief.6

Key Medical Associations Cited:

  • American Pain Society (APS)
  • American Society of Regional Anesthesia and Pain Medicine (ASRA)
  • American Society of Anesthesiologists (ASA)

A novel strategy involves utilizing a combination product of non-opioid analgesics to harness the benefits of a multimodal approach while minimizing the risk of side effects and reliance on opioids6

Harness the Power of Synergy™

COMBOGESIC® IV is a fixed dose combination (FDC) of acetaminophen and ibuprofen that optimizes its synergistic effects through its different mechanisms of action8,9

Advanced Approach to Multimodal Analgesia

  • COMBOGESIC® IV contains active drug substances with different mechanisms of action that harness additive or synergistic effects to provide greater pain relief compared with individual components used as single-modality interventions6,8,9

Unique Formulation

  • COMBOGESIC® IV is the only IV analgesic therapy formulated with 1,000 mg of acetaminophen and 300 mg of ibuprofen, utilizing the synergistic effect of both medicines for optimal pain relief8

Ready-to-Use Administration

  • Readily available solution with no mixing required for administration8
  • Administer as a 15-minute IV infusion, every 6 hours as needed, not to exceed the maximum total daily dose of 4,000 mg acetaminophen and 1,200 mg of ibuprofen in 24 hours8

Harness the synergistic effects of COMBOGESIC® IV

Explore the data

HARNESS THE POWER OF SYNERGY™

acetaminophen + ibuprofen = COMBOGESIC® IV

QUESTIONS ABOUT COMBOGESIC® IV?

Find answers to frequently asked questions and more.

VIEW FAQS

Important Safety Information

WARNING: HEPATOTOXICITY, CARDIOVASCULAR RISK, and GASTROINTESTINAL RISK

  • RISK OF MEDICATION ERRORS: Take care when prescribing, preparing, and administering COMBOGESIC® IV to avoid dosing errors which could result in accidental overdose and death.
  • HEPATOTOXICITY: COMBOGESIC® IV contains acetaminophen which has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most cases of liver injury are associated with doses exceeding 4,000 mg per day and often involve more than one acetaminophen-containing product.
  • CARDIOVASCULAR RISK: COMBOGESIC® IV contains ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID). NSAIDs cause an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.
  • COMBOGESIC® IV is contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
  • GASTROINTESTINAL RISK: NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk.

CONTRAINDICATIONS

COMBOGESIC® IV is contraindicated in:

  • Patients with known hypersensitivity to acetaminophen, ibuprofen, other NSAIDs or to any components of this product.
  • Patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
  • Patients with severe hepatic impairment or severe active liver disease.

WARNINGS & PRECAUTIONS

  • Hepatotoxicity. COMBOGESIC® IV contains acetaminophen and ibuprofen. Acetaminophen has been associated with cases of acute liver failure; the risk is higher in those with underlying liver disease and in those who ingest alcohol. Use in patients with hepatic impairment is not recommended. Elevations of ALT or AST have been reported in NSAID-treated patients.
  • Cardiovascular Thrombotic Events. To minimize the risks of CV events, use the lowest effective dose for the shortest duration possible.
  • Gastrointestinal Bleeding, Ulceration, and Perforation. NSAIDs may cause serious and sometimes fatal GI adverse events at any time and without warning. Avoid use in patients at higher risk. In concomitant use with low-dose aspirin, monitor patients more closely for evidence of GI bleeding.
  • Hypertension. NSAIDs can lead to onset of new hypertension or worsening of pre-existing hypertension, which may contribute to the increased incidence of CV events.
  • Heart Failure and Edema. Avoid use in patients with severe heart failure unless benefits outweigh risk.
  • Renal Toxicity and Hyperkalemia. Use in patients with renal impairment is not recommended. Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Increases in serum potassium concentration, including hyperkalemia, have been reported.
  • Hypersensitivity and Anaphylactic Reactions. Hypersensitivity and anaphylaxis associated with ibuprofen and acetaminophen have been reported, including life-threatening anaphylaxis associated with acetaminophen.
  • Exacerbation of Asthma Related to Aspirin Sensitivity. Patients with asthma may have intolerance to aspirin and other NSAIDs.
  • Serious Skin Reactions. Acetaminophen or NSAIDs may cause serious skin reactions such as exfoliative dermatitis, acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal and may occur without warning. Discontinue the use of COMBOGESIC® IV at the first appearance of skin rash or any other sign of hypersensitivity.
  • Drug Rash with Eosinophilia and Systemic Symptoms (DRESS). DRESS that may be life-threatening or fatal has been reported in patients taking NSAIDs.
  • Fetal Toxicity: Premature Closure of Fetal Ductus Arteriosus. Avoid use of COMBOGESIC® IV in pregnant women at about 30 weeks gestation and later. COMBOGESIC® IV increases the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age.
  • Hematologic Toxicity. Anemia has occurred in NSAID-treated patients and NSAID-treatment may increase the risk of bleeding events.
  • Ophthalmological Effects. Blurred or diminished vision, scotomata, and/or changes in color vision have been reported with oral ibuprofen.
  • Aseptic Meningitis. Aseptic meningitis with fever and coma has been observed in patients on oral ibuprofen.
  • Masking of Inflammation and Fever. Activity of COMBOGESIC® IV in reducing inflammation, and possibly fever, may diminish signs of infections.
  • Laboratory Monitoring. Monitor patients on NSAID treatment with a CBC and a chemistry profile as clinically indicated.

ADVERSE REACTIONS

The most common adverse reactions (≥ 3%) were infusion site pain, nausea, constipation, dizziness, infusion site extravasation, vomiting, headache, and somnolence.

DRUG INTERACTIONS

  • Drugs That Interfere with Hemostasis. Ibuprofen and anticoagulants have a synergistic effect on bleeding. Concomitant use increases the risk of serious bleeding. Concomitant use of drugs that interfere with serotonin reuptake and an NSAID may increase the risk of bleeding.
  • ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers. NSAIDs may diminish the antihypertensive effect of ACE inhibitors, ARBs, or Beta-Blockers. In the elderly, volume depleted, or those that have renal impairment, concomitant use with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure.
  • Diuretics. NSAIDs can reduce the natriuretic effect of loop diuretics and thiazides in some patients.
  • Digoxin. Concomitant use of ibuprofen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.
  • Lithium. NSAIDs produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
  • Methotrexate. Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity.
  • Cyclosporine. Concomitant use of NSAIDS and cyclosporine may increase cyclosporine’s nephrotoxicity.
  • NSAIDs and Salicylates. Concomitant use with other NSAIDs or salicylates increases the risk of GI toxicity.
  • Pemetrexed. Concomitant use of NSAIDS and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity.

INDICATIONS AND USAGE

COMBOGESIC® IV is indicated in adults (over age 18) where an intravenous route of administration is considered clinically necessary for:

  • The relief of mild to moderate pain.
  • The management of moderate to severe pain as an adjunct to opioid analgesics.

INDICATIONS AND USAGE

COMBOGESIC® IV is indicated in adults (over age 18) where an intravenous route of administration is considered clinically necessary for:

  • The relief of mild to moderate pain.
  • The management of moderate to severe pain as an adjunct to opioid analgesics.

LIMITATIONS OF USE

COMBOGESIC® IV is indicated for short-term use of five days or less.

For more information, please see the full Prescribing Information , available at www.hikma.com .

To report an adverse event or product complaint, please contact us at [email protected] or call 1-877-845-0689 or 1-800-962-8364 . Adverse events may also be reported to the FDA directly at 1-800-FDA-1088 or www.fda.gov/medwatch .
References:
  1. Fine M. Quantifying the impact of NSAID-associated adverse events. Am J Manag Care. 2013;19(suppl 14):S267-S72.
  2. Busse JW, Sadeghirad B, Oparin Y, et al. Management of acute pain from non–low back, musculoskeletal injuries. Ann Intern Med. 2020;173(9):730-738. doi:10.7326/M19-3601
  3. Gan TJ. Poorly controlled postoperative pain: prevalence, consequences, and prevention. J Pain Res. 2017;10:2287-2298.
  4. Walton LL, Duff E, Arora RC, McMillan DE. Surgery patients’ perspectives of their role in postoperative pain: a scoping review. Int J Nurs Stud Adv. 2023;5:100124.
  5. Glowacki D. Effective pain management and improvements in patients’ outcomes and satisfaction. Crit Care Nurse. 2015;35(3):33-41. doi:10.4037/ccn2015440
  6. Chou R, Gordon DB, Leon-Casasola OA de, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016;17(2):131-157. doi:10.1016/j.jpain.2015.12.008
  7. Hyland SJ, Wetshtein AM, Grable SJ, Jackson MP. Acute pain management pearls: a focused review for the hospital clinician. Healthcare (Basel). 2022;11(1):34.
  8. COMBOGESIC® IV (acetaminophen 1000 mg and ibuprofen 300 mg) [package insert]. Hikma Pharmaceuticals USA Inc.
  9. Daniels SE, Playne R, Stanescu I, et al. Efficacy and safety of an intravenous acetaminophen/ibuprofen fixed-dose combination after bunionectomy: a randomized, double-blind, factorial, placebo-controlled trial. Clin Ther. 2019;41(10):1982-1995.e8. doi:10.1016/j.clinthera.2019.07.008

Important Safety Information

WARNING: HEPATOTOXICITY, CARDIOVASCULAR RISK, and GASTROINTESTINAL RISK

  • RISK OF MEDICATION ERRORS: Take care when prescribing, preparing, and administering COMBOGESIC® IV to avoid dosing errors which could result in accidental overdose and death.
  • HEPATOTOXICITY: COMBOGESIC® IV contains acetaminophen which has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most cases of liver injury are associated with doses exceeding 4,000 mg per day and often involve more than one acetaminophen-containing product.
  • CARDIOVASCULAR RISK: COMBOGESIC® IV contains ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID). NSAIDs cause an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.
  • COMBOGESIC® IV is contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
  • GASTROINTESTINAL RISK: NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk.
Scroll to Top